Skip to the content
Search
Beyond Type 1
Menu
BEYOND TYPE 1
Show sub menu
About
Board of Directors
The Team
Leadership Council
Portfolio
Press
Careers
Contact
Join Us
Diabetes
Type 1 Info
Type 2 Info
Diabetes Management
Newly Diagnosed
Forms Of Diabetes
Autoimmune Diseases
Pregnancy with Type 1 Diabetes
Research
Resources
Stories
Diabetes News
Diabetes Management
Diabetes + Exercise
Mental Health + Diabetes
Food and Diabetes
School Resources
Sex, Drugs + Rock & Roll
Travel + Adventure
Previously Healthy
GetInsulin.org
Newsletter
Programs
Beyond Type 1 App
Beyond Barriers
Beyond Scholars
Community Table
GetInsulin.org
Marathon Team
Snail Mail Club
TuDiabetes
Type 1 Signs
Jesse Was Here
Advocacy
Donate
Search
Tag:
insulin access
Sanofi to Slash Price of Lantus by 78%, Cap Out-of-Pocket Costs to $35
Sanofi has capped monthly out-of-pocket costs for Lantus to $35 for all with commercial insurance and will cut the price of Lantus by 78%, effective January 1, 2024.
$25 List Price + $35 Copay Caps: Lilly’s New Insulin Cost Reductions
On March 1, 2023, insulin manufacturer Lilly announced expanded insulin cost-saving measures for people with and without health insurance coverage.
Congress Wants You to Know About These New, Cheaper Insulins
This legislation aims to help you and your doctor understand the potential benefits of cost-saving biosimiliar drugs and how to access them.
Insulin Prices are Rising Unchecked. New Biosimilar Insulins May Cost You Less.
New biosimilar insulins stand to offer lower-cost alternatives for people who rely on on insulin to stay alive.
Interchangeable Insulin: Here’s What You Need to Know
You may soon be able to substitute newer, cheaper insulins that work exactly the same as your current prescription.
What is Biosimilar Insulin?
The launch of biosimilar insulins will expand options for people with diabetes and may drive competition amid soaring prices at the pharmacy.
Another Reminder that Racial/Ethnic Inequality Exists in Diabetes Care
Despite the variety of diabetes medications and technology, race and ethnicity still weigh heavily on a person’s access to these life-saving tools.
Access to Insulin: In Low-Income Countries
In many countries, a person with diabetes may walk for four days to get a vial of short-acting insulin and seven to 10 days for long-acting.
Access to Insulin: In the United States
Despite the growing variety of insulin and technology, access to this life-saving drug continues to be a dire problem in the United States.
Drug Rebates, Insulin and Affording Life with Diabetes in the United States
The issues surrounding drug rebates in the U.S. highlight the need for reform, especially when it comes to insulin and living with diabetes.
The Affordable Insulin Now Act: A Step Toward Federal Legislation
The Affordable Insulin Now Act, if passed in its current form, could help bring down the cost of insulin for millions of insured people with diabetes.
Civica Rx Aims to Bring $30 Insulin to Market in 2024
Launching to market in 2024, Civica Rx aims to make insulin available for no more than $30 per vial, regardless of insurance status.
How Civica Rx Aims to Change the U.S. Insulin Market
We sat down with Civica Rx board chair Dan Liljenquist to talk about how Civica Rx aims to create modern insulins for $30 or less per vial.
Walmart Launches Lower-Cost Analog Insulin: ReliOn NovoLog
ReliOn NovoLog will be available at Walmart and Sam's Club pharmacies for $72.88 per vial and $85.88 per box of five FlexPens.
All About State-Based Insulin Price Cap Laws
While we advocate for federal actions on insulin pricing, state based insulin price cap laws are leading the charge.
Posts navigation
←
Newer
Posts
1
2
Older
Posts
→